Comparative effectiveness of 18F-FDG PET/CT versus whole-body MRI for detection of malignant peripheral nerve sheath tumors in neurofibromatosis type 1

Clinical Nuclear Medicine

Volumn 38, Issue 1, 2013, Pages

  Derlin, Thorsten ^a   Tornquist, Katharina ^a   Münster, Silvia ^a   Apostolova, Ivayla ^b   Hagel, Christian ^a   Friedrich, Reinhard E ^a   Wedegärtner, Ulrike ^a   Mautner, Victor F ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

heterogeneity; MPNST; neurofibromatosis; PET CT; sarcoma; whole body MRI

Indexed keywords

CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18; GADOLINIUM PENTETATE; GASTROLUX; IOMEPROL; MAGNEGITA; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT;

ADULT; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; MALE; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; NEUROFIBROMATOSIS; REPRODUCIBILITY; SENSITIVITY ANALYSIS; TUMOR VOLUME; WHOLE BODY MRI; ADOLESCENT; CHILD; COMPARATIVE STUDY; MIDDLE AGED; NERVE SHEATH TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PRESCHOOL CHILD; RADIOGRAPHY; SCINTISCANNING;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; COMPARATIVE EFFECTIVENESS RESEARCH; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NERVE SHEATH NEOPLASMS; NEUROFIBROMATOSIS 1; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; REPRODUCIBILITY OF RESULTS; YOUNG ADULT;

EID: 84871652695     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e318266ce84     Document Type: Article

References (24)

1. Lammert M, Friedman JM, Kluwe L, et al. Prevalence of neurofibromatosis 1 in German children at elementary school enrollment. Arch Dermatol. 2005;141: 71-74. (Pubitemid 40144442)
2. 18F]FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1. Eur J Nucl Med Mol Imaging. 2009;36:751-757.
3. Lott IT, Richardson EP Jr. Neuropathological findings and the biology of neurofibromatosis. Adv Neurol. 1981;29:23-32.
4. Mautner VF, Hartmann M, Kluwe L, et al. MRI growth patterns of plexiform neurofibromas in patients with neurofibromatosis type. Neuroradiology. 2006;48:160-165. (Pubitemid 43380228)
5. Mautner VF, Asuagbor FA, Dombi E, et al. Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis. Neuro Oncol. 2008; 10:593-598.
6. Evans DG, Baser ME, McGaughran J, et al. Malignant peripheral nerve sheath tumours in neurofibromatosis. J Med Genet. 2002;39:311-314. (Pubitemid 34526349)
7. WongWW, Hirose T, Scheithauer BW, et al. Malignant peripheral nerve sheath tumor: analysis of treatment outcome. Int J Radiat Oncol Biol Phys. 1998;42: 351-360. (Pubitemid 28502782)
8. Ducatman BS, Scheithauer BW, Piepgras DG, et al. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer. 1986;57: 2006-2021. (Pubitemid 16113778)
9. Benz MR, Tchekmedyian N, Eilber FC, et al. Utilization of positron emission tomography in the management of patients with sarcoma. Curr Opin Oncol. 2009;21:345-351.
10. Ferner RE, Gutmann DH. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res. 2002;62:1573-1577. (Pubitemid 34407825)
11. 18F]2-Fluoro-2-deoxy- D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. Ann Oncol. 2008;19:390-394. (Pubitemid 351201726)
12. BrennerW, Friedrich RE, Gawad KA, et al. Prognostic relevance of FDG PETin patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours. Eur J Nucl Med Mol Imaging. 2006;33:428-432.
13. Cai W, Kassarjian A, Bredella MA, et al. Tumor burden in patients with neurofibromatosis types 1 and 2 and schwannomatosis: determination on wholebody MR images. Radiology. 2009;250:665-673.
14. Jaremko JL, Macmahon PJ, Torriani M, et al. Whole-body MRI in neurofibromatosis: incidental findings and prevalence of scoliosis. Skeletal Radiol. 2011;41:917-923.
15. Matsumine A, Kusuzaki K, Nakamura T, et al. Differentiation between neurofibromas and malignant peripheral nerve sheath tumors in neurofibromatosis 1 evaluated by MRI. J Cancer Res Clin Oncol. 2009;135:891-900.
16. Friedrich RE, Kluwe L, Funsterer C, et al. Malignant peripheral nerve sheath tumors (MPNST) in neurofibromatosis type 1 (NF1): diagnostic findings on magnetic resonance images and mutation analysis of the NF1 gene. Anticancer Res. 2005;25:1699-1702. (Pubitemid 40896788)
17. Wasa J, Nishida Y, Tsukushi S, et al. MRI features in the differentiation of malignant peripheral nerve sheath tumors and neurofibromas. AJR Am J Roentgenol. 2010;194:1568-1574.
18. Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol. 1988;45:575-578.
19. Trojani M, Contesso G, Coindre JM, et al. Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer. 1984;33:37-42. (Pubitemid 14223231)
20. Lin BT,Weiss LM, Medeiros LJ. Neurofibroma and cellular neurofibroma with atypia: a report of 14 tumors. Am J Surg Pathol. 1997;21:1443-1449.
21. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-174. (Pubitemid 8054849)
22. Korf BR. Plexiform neurofibromas. Am J Med Genet. 1999;89:31-37. (Pubitemid 30033174)
23. Eary JF, Link JM, Muzi M, et al. Multiagent PET for risk characterization in sarcoma. J Nucl Med. 2011;52:541-546.
24. Benz MR, Czernin J, Dry SM, et al. Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign. Cancer. 2010;116:451-458.